<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00725348</url>
  </required_header>
  <id_info>
    <org_study_id>BT0700NED001</org_study_id>
    <nct_id>NCT00725348</nct_id>
  </id_info>
  <brief_title>An Open-Label, Multi-Center Trial in the Treatment of Subjects With Moderate to Severe Plaque Type Psoriasis</brief_title>
  <official_title>An Open-Label, Multi-Center Pilot Trial to Assess the Efficacy and Safety of Oral R115866 in the Treatment of Subjects With Moderate to Severe Plaque Type Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stiefel, a GSK Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of a new oral drug used for the treatment of psoriasis. All subjects will get
      active medication, there is no placebo arm.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PASI Scores</measure>
    <time_frame>Various Visits</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R115866</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talarozole</intervention_name>
    <description>1.0 mg oral dose per day</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Rambazole</other_name>
    <other_name>R115866</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female of non-childbearing potential (at least 2 years post-menopausal or
             undergone successful surgical sterilization at least 1 year before inclusion)

          -  Presence of moderate to severe plaque psoriasis with a PASI of at least 5

        Exclusion Criteria:

          -  Pustular, guttate or other non-plaque forms of psoriasis or psoriatic arthritis

          -  Significant coexisting hepatic, renal, or bone marrow disease, hyperlipidemia, chronic
             pancreatitis, osteoporosis, or a history indicating adrenal cortex dysfunction or any
             other serious disease (including cancer and subjects known to be HIV positive)

          -  History of heart failure, myocardial infarction within the past six months, cardiac
             arrhythmia, or under treatment for heart disorders

          -  Clinically significant abnormal ECG-intervals or morphology of the ECG; QT or QTc &gt;470
             ms in females or &gt;450 ms in males

          -  Use of vitamin A (&gt;1000 Âµg/day), phenytoin, carbamazepine, warfarin, rifampicin,
             tetracyclines, ketoconazole, itraconazole, astemizole, terfenadine, cisapride,
             anti-psychotics, anti-depressants, lithium, antimalarials, alpha-blocking drugs,
             angiotensin-converting enzyme inhibitors, cyclosporin A, glucocorticosteroids and
             non-steroidal anti-inflammatory drugs, non-potassium-sparing diuretics

          -  Previous use of any systemic immunomodulatory therapy (biologicals) or psoriasis
             vaccine

          -  Use of other systemic therapy for psoriasis (e.g. PUVA, systemic steroids, cyclosporin
             A, methotrexate, retinoids) within four weeks prior to Visit 2

          -  Use of UV therapy or excessive UV exposure or topical therapy for psoriasis other than
             bland emollients within two weeks prior to Visit 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. P. van de Kerkhof, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nijmegen, Maastricht, The Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Nijmegen Sint Radboud</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2008</study_first_submitted>
  <study_first_submitted_qc>July 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2008</study_first_posted>
  <last_update_submitted>September 23, 2011</last_update_submitted>
  <last_update_submitted_qc>September 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>R 115866</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

